Important Safety Information Full Prescribing Information


Eisai Professional and Patient Resources

A variety of resources for your entire team

Eisai Medical Services Department

Answers to healthcare professionals’ questions about ALOXI.

  • Phone: 1-888-422-4743
  • Available Monday-Friday, 8:30 AM - 8 PM (ET)

Eisai Assistance Program

A dedicated resource to help minimize payor access and coverage challenges, as well as provide information about patient assistance.

Eisai Contract Opportunities

Contact your ALOXI sales representative for information about contract opportunities within the hospital and clinic setting.

Eisai’s Medical Education Grants Program

Provides financial support for educational initiatives that support healthcare provider education, advance the quality of patient care, and align with Eisai’s therapeutic or clinical interests.

Patient support at every step

NSider Patient Education Tool

A cancer patient education resource for nurses developed by an advisory board of experienced oncology nurses in conjunction with Eisai.

Patient Education

Information and resources to help patients better understand risk factors for CINV and strategies for prevention.

Indication

In adults, ALOXI® (palonosetron HCl) injection 0.25 mg is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.

Important Safety Information

  • Aloxi is contraindicated in patients known to have hypersensitivity to the drug of any of its components
  • Most commonly reported adverse reactions in chemotherapy-induced nausea and vomiting include headache (9%) and constipation (5%)

For more information about ALOXI, please see Full Prescribing Information